MYOV News and Press, Myovant Sciences Ltd. From 10/03/22

Myovant Sciences ( NYSE: MYOV ) jumped 32% and traded above Sumitovant Biopharma's $22.75/share offer as analysts see the potential for an increased bid and possible interest from partner Pfizer ( PFE ). "In our view, we think Sumitovant’s offer appears s...

U.K.-based biotech Myovant Sciences Ltd. ( NYSE: MYOV ) added ~32% pre-market Monday on rising volumes after the company announced that its board declined a $2.4B takeover offer from Sumitovant Biopharma, a unit of Japan-based Sumitomo Pharma. 100.3K company shares hav...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: f11photo/Shutterstock.com We’re starting off the week with a breakdown of the biggest pre-market stock movers for Monday morning! Moving stocks this morning are a buyout offer, the end of a merger agr...

Myovant Sciences ( NYSE: MYOV ) said a special committee of its board rejected a $22.75/share offer from Sumitovant Biopharma to buy the remaining shares of the biopharma company it doesn't already own. Sumitovant currently holds approximately 52% of the outstanding s...

BASEL, Switzerland, Oct. 02, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences Ltd. (NYSE: MYOV) (the “Company”) confirmed today that it has received a preliminary, non-binding proposal (the “Proposal”) from Sumitovant Biopharma Ltd. (“Sumitovant”) and Sumi...

Summary The compelling results of endometriosis treatment MYFEMBREE's phase 3 led to the drug's approval, and Myovant will be eligible for up to $200 million based on achieving certain milestones. The endometriosis market currently has few competitors, and more generally, there ar...

BASEL, Switzerland, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) today announced an educational campaign to inspire prostate cancer patients to speak up and seek support through authentic conversations, along with the sponsorship of educational opportunities fo...

BASEL, Switzerland, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy, today announced that David Marek, Chi...

Summary Myovant secured FDA approval for Myfembree for the treatment of endometriosis in early August. The approval clears the regulatory overhang on the stock but now comes the harder part - commercialization of Myfembree in this indication. Orgovyx continues to produce stron...

SVB Securities has upgraded Myovant Securities ( NYSE: MYOV ) to outperform from market perform due to the recent approval of Myfembree for pain associated with endometriosis and tailwinds from an existing approval in in uterine fibroids. The firm also upgraded the pri...